TaiAn Technologies Corporation

AnBogen Therapeutics is a clinical-stage biotechnology company focused on developing precision anti-cancer drugs aimed at addressing unmet medical needs in oncology. The company is dedicated to creating innovative therapies that not only seek to cure various cancers but also enhance the quality of life for patients worldwide. AnBogen works to bridge the gap between research and clinical development by advancing a pipeline of oncology inhibitors specifically designed to treat lung cancer, thereby contributing to the field of precision oncology.

Developer of innovative protein degradation drugs designed to treat cancer, neurodegenerative and aging-related diseases. The company develops a drug pipeline, using an AI-enabled platform to discover drug candidates, which target and degrade disease-related proteins, enabling researchers, clinicians, and pharmaceutical companies to access a novel class of drugs that address life-threatening and life-impairing diseases plagued by drug resistance.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on the research, development, and manufacturing of innovative diagnostic tools for the detection of neurological diseases. Established in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, the company specializes in advanced imaging techniques, notably the 18F-PM-PBB3 tau positron-emission tomography (PET) imaging tracer. This tracer aids in diagnosing tauopathies and supports the development of therapeutic programs for conditions such as Alzheimer's disease, Parkinson's disease, and dementia. Additionally, Aprinoia manufactures an alpha-synuclein PET imaging tracer. The company's mission is to enhance brain health and improve clinical outcomes for patients suffering from various neurodegenerative diseases by leveraging precision medicine to target harmful protein aggregates involved in these conditions.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.